Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent's Hospital Melbourne, Melbourne, Australia, briefly discusses the current standard of care for patients with lower-risk myelodysplastic syndromes (MDS), drawing focus on the importance of supportive care, reducing cytopenia, and improving quality of life. Dr Tan also mentions promising novel agents in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть